A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting

Phase 2

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionA Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05787574

Conditions

Primary Immune Regulatory Disorder

Autoimmune Lymphoproliferative

Immune System Diseases

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Emapalumab

Fludarabine and Dexamethasone

Stem Cell Transplant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-03-25.